Hemodialysis-resistant hypertension: control with an orally active inhibitor of angiotensin-converting enzyme

J Clin Endocrinol Metab. 1979 May;48(5):869-71. doi: 10.1210/jcem-48-5-869.

Abstract

In two patients with end stage renal disease and dialysis-resistant hypertension, the orally active inhibitor of angiotensin-converting enzyme, captopril (SQ14,225; 2-D-methyl-3-mercaptopropranoyl-L-proline, dramatically lowered blood pressure both before and during dialysis. This agent holds promise as an alternate to bilateral nephrectomy in such patients.

Publication types

  • Case Reports
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Angiotensin-Converting Enzyme Inhibitors*
  • Antihypertensive Agents / therapeutic use*
  • Female
  • Glomerulonephritis / complications
  • Humans
  • Hypertension, Renal / drug therapy*
  • Hypertension, Renal / etiology
  • Male
  • Nephrosclerosis / complications
  • Proline / analogs & derivatives*
  • Proline / therapeutic use
  • Renal Dialysis

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Proline